Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Enanta Pharmaceuticals (ENTA) PT Lowered to $85 at RBC Capital
November 28, 2018 6:36 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $85.00 (from $92.00) while maintaining a Sector Perform rating.
... MoreEnanta Pharma (ENTA) Tops Q4 EPS by 11c, Revenues Miss
November 26, 2018 4:02 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $1.30, $0.11 better than the analyst estimate of $1.19. Revenue for the quarter came in at $67.2 million versus the consensus estimate of $68.52 million.
Enanta has never been in a stronger position from both a financial and clinical... More
